Liver Reference Set Application (Rapid): Block - Drexel Univ (2008)
285
GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers
Case/control
Proteomics
G.I. and Other Associated Cancers Research Group
1
The goal of this application is to determine if the levels of serum GP73 and fucosylated kininogen/acute phase proteins can be used to detect hepatocellular carcinoma (HCC) in the background of liver cirrhosis. The use of the validation set would allow us to directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers
Directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers
For data analysis, Receiver Operating Curves (ROC) should be generated for the Gp73 and fucosylated kininogen either alone and in combination with AFP, AFP-L3 and DCP and the area under the curve determined (AUROC). No training sets will be required. Markers will be directly compared by their AUROC values and ranked accordingly. The following will be criteria for advancement of a biomarker status and further testing: Statistically significant with alpha = 10% AUROC improvement in the distinction of cirrhosis from HCC with the addition of marker(s) to AFP alone for the full set of samples OR in defined subsets, e.g. AFP negatives, early tumor stage. The ultimate target is to find a combination of markers that will improve on current AFP-alone sensitivity and specificity, such that we will be able to achieve > 90% sensitivity and > 85% specificity for the distinction of cirrhosis from HCC.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
